Skip to content
Citation only via Europe PMC

Osteosarcopenia as a Systems-Level Failure of the Bone-Muscle Functional Unit.

Dai H, Liu J, Zang W, Tan LF, Koh F, Knapp KM, Zhu C, Zhang W, Zhu J, Zhang X.

Current osteoporosis reports · 2026

Abstract

<h4>Purpose of review</h4>Osteosarcopenia-osteoporosis co-occurring with sarcopenia-has a pooled prevalence of 18.5% in older adults (range 5-37%) and carries increased risks of fracture (HR 2.13, 95% CI 1.61-2.81), falls (HR 1.54, 95% CI 1.20-1.97), and mortality (HR 1.75, 95% CI 1.34-2.28). Often framed as simple coexistence, osteosarcopenia is proposed as a systems-level disorder of interconnected bone-muscle degeneration.<h4>Recent findings</h4>We synthesize evidence from molecular biology, systems physiology, and translational research showing that osteosarcopenia is a systems-level failure of the bone-muscle functional unit, a highly integrated structure maintained by bidirectional mechanical coupling, osteokine-myokine exchange, and shared intracellular signaling pathways. We examine how intrinsic aging mechanisms (genomic and epigenetic drift, transcriptional reprogramming, structural co-degeneration, and metabolic-mechanical decoupling) and systemic drivers (inflammaging(definition), adipose dysfunction, gut dysbiosis, and hormonal decline) converge to reconfigure this crosstalk from a homeostatic regulator into a pathological amplifier. At the center of this process is a vicious cycle of declining osteocalcin and irisin alongside rising sclerostin, FGF23, and myostatin, propagated through shared signaling hubs (Wnt/β-catenin, TGF-β/Smad, IGF-1/Akt/FOXO, and NF-κB) and sustained by gut-bone-muscle axes. We advance this systems-level framing as an integrative hypothesis rather than established fact: more-than-additive risk and synergistic treatment effects are not yet demonstrated in humans. Actionable now are dual-tissue screening, guideline-based treatment of each component, and combined exercise and nutritional strategies; biomarker-guided care and crosstalk-targeted pharmacology await prospective validation.<h4>Evidence level</h4>Mechanistic claims in this review are primarily supported by preclinical evidence; human causal evidence remains incomplete. Full statement in Online Resource 1.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
Europe PMC
DOI
10.1007/s11914-026-00991-0
Canonical
link ↗
Fetched
2026-11-05 MST

Cite this

APA
H, D., J, L., W, Z., LF, T., F, K., KM, K., C, Z., W, Z., J, Z., &amp; X., Z. (2026). Osteosarcopenia as a Systems-Level Failure of the Bone-Muscle Functional Unit. <em>Current osteoporosis reports</em>. https://doi.org/10.1007/s11914-026-00991-0
Vancouver
H D, J L, W Z, LF T, F K, KM K, et al. Osteosarcopenia as a Systems-Level Failure of the Bone-Muscle Functional Unit. Current osteoporosis reports. 2026. doi:10.1007/s11914-026-00991-0.
BibTeX
@article{dai2026Osteos, title = {Osteosarcopenia as a Systems-Level Failure of the Bone-Muscle Functional Unit.}, author = {Dai H and Liu J and Zang W and Tan LF and Koh F and Knapp KM and Zhu C and Zhang W and Zhu J and Zhang X.}, journal = {Current osteoporosis reports}, year = {2026}, doi = {10.1007/s11914-026-00991-0}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings